- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
North Chicago Today
By the People, for the People
Allergan Aesthetics Presents New Data on Neurotoxin and Weight Loss Aesthetics at AAD Meeting
Findings highlight safety and efficacy of investigational TrenibotE and insights on growing GLP-1 agonist patient population seeking aesthetic treatments.
Mar. 30, 2026 at 2:06pm
Got story updates? Submit your updates here. ›
Allergan Aesthetics, an AbbVie company, presented four posters at the American Academy of Dermatology Meeting (AAD), highlighting the safety and efficacy of new and emerging products in their aesthetics portfolio and insights on the aesthetic mindset of an emerging patient population. The data included findings on the investigational neurotoxin trenibotulinumtoxinE (TrenibotE) and characteristics of patients receiving GLP-1 agonists for weight loss who are seeking aesthetic treatments.
Why it matters
As the aesthetics market continues to evolve, Allergan Aesthetics' research provides valuable insights into emerging treatment options and patient behaviors. Understanding the safety and efficacy of new neurotoxins like TrenibotE, as well as the growing demand for aesthetic treatments among GLP-1 agonist patients, can help guide future product development and patient care strategies.
The details
The TrenibotE data came from an 18-week, open-label, Phase 3 study evaluating the safety and efficacy of repeat treatments for glabellar lines. Key findings showed TrenibotE was well-tolerated, had a consistent safety profile, and demonstrated rapid and consistent efficacy over 3 sequential treatments. The data on GLP-1 agonist patients seeking aesthetic treatments was obtained from a survey of healthcare professionals. It found this patient population is growing rapidly across aesthetic specialties, with 52% of GLP-1 patients expressing concerns about their facial appearance. Barriers to treatment include cost and fear of unnatural results.
- The AAD meeting took place on March 30, 2026.
The players
Allergan Aesthetics
An AbbVie company that develops, manufactures, and markets a portfolio of leading aesthetics brands and products.
John Maltman, Ph.D.
Vice president, global aesthetics medical affairs at Allergan Aesthetics.
What they’re saying
“At Allergan Aesthetics, we are dedicated to scientific research that reinforces customer and patient trust and confidence in our broad product portfolio. Our data presented at AAD advance knowledge of our market-leading and emerging portfolio to deliver safe and effective treatments that address patients' aesthetic concerns.”
— John Maltman, Vice president, global aesthetics medical affairs
What’s next
If approved, TrenibotE would be the first neurotoxin of its kind available to patients, offering a new option for treating glabellar lines.
The takeaway
Allergan Aesthetics' research highlights the evolving aesthetics market, with growing demand for treatments that address concerns related to weight loss medications and the potential for innovative neurotoxins to provide rapid, effective, and safe solutions for common aesthetic issues.
